{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dacarbazine&page=2",
    "query": {
      "intervention": "dacarbazine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dacarbazine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T20:03:57.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01977677",
      "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Ependymoblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Medulloblastoma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglial Tumors",
        "Adult Pineoblastoma",
        "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Lawrence Recht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-11",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01977677"
    },
    {
      "nct_id": "NCT01120639",
      "title": "Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Cancer of Brain and Nervous System",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Radiosurgery (SRS)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-04",
      "completion_date": "2020-11-15",
      "has_results": true,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120639"
    },
    {
      "nct_id": "NCT03011671",
      "title": "Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma of Brain"
      ],
      "interventions": [
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-10-03",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011671"
    },
    {
      "nct_id": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)",
        "Melanoma Stage IIIB-IV",
        "Cutaneous Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "LNS8801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy (dacarbazine or temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy (Pembrolizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (nivolumab and relatlimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (ipilimumab and nivolumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2025-08-06",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06624644"
    },
    {
      "nct_id": "NCT02392793",
      "title": "Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Peg-filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Months to 25 Years"
      },
      "enrollment_count": 43,
      "start_date": "2015-03-25",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392793"
    },
    {
      "nct_id": "NCT00574964",
      "title": "Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Gliadel Wafer, Temodar and Radiotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574964"
    },
    {
      "nct_id": "NCT00612339",
      "title": "Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Avastin and Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2007-08",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612339"
    },
    {
      "nct_id": "NCT00098436",
      "title": "Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "laromustine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vion Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2004-09",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098436"
    },
    {
      "nct_id": "NCT00077454",
      "title": "Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Malignant Germ Cell Tumor",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 95,
      "start_date": "2004-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00077454"
    },
    {
      "nct_id": "NCT05588453",
      "title": "Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Natural Killer Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kari Kendra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-03-01",
      "completion_date": "2027-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-09-23T20:03:57.362Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05588453"
    }
  ]
}